ARDX — Ardelyx, Inc.

Summary of ARDX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $407.3 million for 2025, up 22% from $333.6 million in 2024.
• IBSRELA Revenue: $274.2 million, a 73% increase year-over-year.
• XPHOZAH Revenue: $103.6 million, down 36% due to loss of Medicare Part D reimbursement for approximately 60% of its patient base.
• Net Loss: $61.6 million ($0.26 per share), compared to a net loss of $39.1 million ($0.17 per share) in 2024.
• Cash Position: $264.7 million at year-end, an increase from $250.1 million in 2024. Positive cash flow generated in the last two quarters of 2025.

2. Strategic Updates and Business Highlights

• IBSRELA Growth: Significant growth momentum with a 61% increase in Q4 2025. The drug is positioned as a first-in-class treatment for IBS-C, with a robust market opportunity.
• XPHOZAH Strategy: Focus on maintaining patient access and increasing total dispenses, achieving a 9% increase in total dispenses year-over-year.
• New Patent: A new patent for IBSRELA and XPHOZAH formulations, expiring in 2042, strengthens the company’s intellectual property strategy.
• Pipeline Development: Initiated a Phase III trial for IBSRELA to expand its indication to chronic idiopathic constipation (CIC) and commenced development for a next-generation NHE3 inhibitor, RDX-10531.

3. Forward Guidance and Outlook

• 2026 Revenue Projections: IBSRELA expected to generate between $410 million and $430 million, representing at least 50% year-over-year growth.
• Long-term Aspirations: IBSRELA projected to reach $1 billion in revenue by 2029, with a compound annual growth rate (CAGR) of 38% thereafter.
• XPHOZAH Guidance: Expected revenues between $110 million and $120 million in 2026, with a long-term target of $750 million before patent expiration in 2034.

4. Challenges and Points of Concern

• XPHOZAH Revenue Decline: The significant drop in revenue due to the loss of Medicare reimbursement remains a concern, impacting overall financial performance.
• Market Dynamics: Anticipated challenges in Q1 2026 due to co-pay resets and insurance changes, which historically affect the IBS-C market.
• Increased Operating Expenses: Projected operating expenses to increase by approximately 25% in 2026, raising concerns about cash flow sustainability despite revenue growth.

5. Notable Q&A Insights

• Confidence in IBSRELA Growth: Management expressed strong confidence in reaching revenue guidance due to the large patient population needing alternatives to existing treatments.
• CIC Trial Expectations: The trial is powered at 95%, with a focus on achieving a durable response in chronic idiopathic constipation patients.
• Market Access Strategy: The company is not pursuing frontline therapy for IBSRELA but aims to solidify its position as a preferred treatment option post-generic utilization.
• Intellectual Property Strategy: The recent patent issuance is seen as a critical step in reinforcing the company’s market position against potential competition.

Overall, Ardelyx demonstrated strong growth in 2025, particularly with IBSRELA, while facing challenges with XPHOZAH's revenue. The company is optimistic about future growth driven by strategic initiatives and pipeline developments.